MGO One Seven LLC Acquires Shares of 525 argenx SE (NASDAQ:ARGX)

MGO One Seven LLC acquired a new stake in argenx SE (NASDAQ:ARGX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 525 shares of the company’s stock, valued at approximately $323,000.

Other institutional investors have also recently bought and sold shares of the company. GeoWealth Management LLC lifted its holdings in shares of argenx by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after acquiring an additional 18 shares during the period. Steward Partners Investment Advisory LLC lifted its holdings in shares of argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock worth $234,000 after acquiring an additional 20 shares during the period. SG Americas Securities LLC lifted its holdings in shares of argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after acquiring an additional 21 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of argenx by 38.2% during the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock worth $47,000 after acquiring an additional 21 shares during the period. Finally, Dynasty Wealth Management LLC lifted its holdings in shares of argenx by 3.4% during the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock worth $416,000 after acquiring an additional 22 shares during the period. Institutional investors own 60.32% of the company’s stock.

argenx Price Performance

Shares of argenx stock opened at $620.97 on Tuesday. argenx SE has a one year low of $352.77 and a one year high of $678.21. The stock’s 50-day moving average is $597.89 and its 200 day moving average is $609.60. The firm has a market cap of $37.92 billion, a price-to-earnings ratio of -705.65 and a beta of 0.60.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. On average, sell-side analysts expect that argenx SE will post 3.13 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ARGX. HC Wainwright reaffirmed a “buy” rating and set a $720.00 price target on shares of argenx in a report on Tuesday, April 8th. Oppenheimer upped their price objective on shares of argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Wedbush restated an “outperform” rating and issued a $715.00 target price on shares of argenx in a research report on Friday, April 11th. Wells Fargo & Company increased their price target on argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. Finally, Sanford C. Bernstein upgraded argenx from a “market perform” rating to an “outperform” rating in a research report on Monday, March 17th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $699.28.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.